Spontaneous bacterial peritonitis cost-effectiveness of therapy: Difference between revisions
m Bot: Removing from Primary care |
|||
(2 intermediate revisions by 2 users not shown) | |||
Line 8: | Line 8: | ||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
* Norfloxacin prophylaxis resulted in savings between $2216 and $8545 per patient per year, depending on the patient group studied. | * Norfloxacin prophylaxis resulted in savings between $2216 and $8545 per patient per year, depending on the patient group studied. | ||
* Trimethoprim-sulfamethoxazole prophylaxis resulted in savings between $2934 and $9251 per patient per year. <ref> | * Trimethoprim-sulfamethoxazole prophylaxis resulted in savings between $2934 and $9251 per patient per year. <ref name="pmid9322524">{{cite journal |author=Inadomi J, Sonnenberg A |title=Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis |journal=Gastroenterology |volume=113 |issue=4 |pages=1289–94 |year=1997 |month=October |pmid=9322524 |doi= |url=}}</ref> | ||
* Abdominal [[paracentesis]] with appropriate ascitic fluid analysis is probably the most rapid and cost-effective method of diagnosing the cause of [[ascites]] | * Abdominal [[paracentesis]] with appropriate ascitic fluid analysis is probably the most rapid and cost-effective method of diagnosing the cause of [[ascites]] | ||
* Regular infusions of [[albumin]] for treatment of new-onset or [[refractory ascites]] should be considered experimental until more studies demonstrate efficacy and cost-effectiveness. | * Regular infusions of [[albumin]] for treatment of new-onset or [[refractory ascites]] should be considered experimental until more studies demonstrate efficacy and cost-effectiveness. | ||
Line 19: | Line 19: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Grammar]] | [[Category:Grammar]] | ||
[[Category:Emergency mdicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] |
Latest revision as of 00:14, 30 July 2020
Spontaneous bacterial peritonitis Microchapters |
Differentiating Spontaneous bacterial peritonitis from other Diseases |
Diagnosis |
Treatment |
Spontaneous bacterial peritonitis cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Spontaneous bacterial peritonitis cost-effectiveness of therapy |
FDA on Spontaneous bacterial peritonitis cost-effectiveness of therapy |
CDC on Spontaneous bacterial peritonitis cost-effectiveness of therapy |
Spontaneous bacterial peritonitis cost-effectiveness of therapy in the news |
Blogs on Spontaneous bacterial peritonitis cost-effectiveness of therapy |
Directions to Hospitals Treating Spontaneous bacterial peritonitis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
The use of prophylactic antibiotics to decrease the incidence of spontaneous bacterial peritonitis is a cost-saving strategy in patients with cirrhosis and ascites.
Cost-Effectiveness of Therapy
- Norfloxacin prophylaxis resulted in savings between $2216 and $8545 per patient per year, depending on the patient group studied.
- Trimethoprim-sulfamethoxazole prophylaxis resulted in savings between $2934 and $9251 per patient per year. [1]
- Abdominal paracentesis with appropriate ascitic fluid analysis is probably the most rapid and cost-effective method of diagnosing the cause of ascites
- Regular infusions of albumin for treatment of new-onset or refractory ascites should be considered experimental until more studies demonstrate efficacy and cost-effectiveness.
- Intravenous ciprofloxacin followed by oral administration of this drug was found to be more cost-effective compared to intravenous ceftazidime in a randomized trial in patients who had not received quinolone prophylaxis.
- Selective intestinal decontamination with norfloxacin or trimethoprim/sulfamethoxazole in patients with prior spontaneous bacterial peritonitis (SBP) or low-protein ascitic fluid does appear to be cost-effective. [2]